Hepatology

Increased serum TBA levels at baseline significantly raised the risk of HCC development in patients with multi-etiology cirrhosis.

These data on metabolic dysfunction-associated steatotic liver disease provide information on the economic burden among high-risk patients.

The study found that, following gradual policy changes, children with acute liver failure requiring a transplant now face a reduced risk of both mortality and graft failure from 1989.

Findings highlight the potential utility of the FAST score for ruling out fibrotic MASH, pointing to the need for a sequential testing approach to rule it in.

The burden of LC-MASLD has significantly increased, especially in economically disadvantaged countries.

This analysis may help identify at-risk patients of liver enzyme elevation following sustained virologic response among individuals with hepatitis C virus infection.

A new study highlights suboptimal HDV screening rates in HBV-infected individuals, suggesting that treating HBV may improve survival for those with HDV coinfection.

Study findings showed children with both obesity and MASLD have a greater risk of youth-onset type 2 diabetes than those with obesity alone.

New phase 2b data highlight denifanstat’s impact on histological features of MASH, meeting both fibrosis improvement and MASH resolution primary endpoints.

Findings support the feasibility and clinical performance of Xpert HCV, the first FDA-approved point-of-care test for diagnosing HCV, in a nonclinical justice setting.

The designation was granted to Mirum Pharmaceuticals based on a positive interim analysis of the phase 2b VANTAGE study of volixibat.

In addition to the Breakthrough Therapy Designation, Boehringer Ingelheim announced the initiation of 2 phase 3 trials in adults with MASH and fibrosis and compensated MASH cirrhosis.

Findings highlight HCV infection burden among people without injection drug use, a known risk factor for HCV, and call for universal testing to better capture these individuals.

Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.

Compared with other international guidelines, the 2024 World Health Organization HBV guidelines had the highest treatment eligibility rates.

This month in review spotlights HCPLive’s coverage of the top hepatic pipeline news and research from September, covering hepatitis, PBC, MASH/MASLD, and more.

Positive 120-day data from the phase 2a study of CNP-104 in PBC highlight its efficacy across multiple immunological and clinical measurements

Compared to those without SLD, patients with MASLD, MetALD, and other combination etiology had a greater risk of developing liver and gastrointestinal cancers.

HBV education led by healthcare providers, decentralized testing, and strategies with more framework-driven mechanisms had the greatest impact on testing uptake.

Physicians who received pharmaceutical industry payments related to 4 different direct-acting antivirals were more likely to prescribe these medications.

Findings from the prospective cohort study suggest the value of serum Z polymer levels as a non-invasive disease-specific biomarker in patients with homozygous ZZ AATD liver disease.

Magnetic resonance elastography and transient elastography did not accurately predict high-grade fibrosis on liver biopsy in children with MASLD.

Heplisav-B provided a greater vaccine completion rate and higher HBV seroprotection than the conventional 3-dose Recombivax HB in thoracic organ transplant candidates.

Meta-analysis findings suggest a significant association between MASLD and serious bacterial infection risk.

Obesity and advanced fibrosis were independent predictors of impaired health-related quality of life in people with T2D.